Germany-based Biofrontera has filed to raise $30 million in a U.S. IPO.
The firm is commercializing Ameluz, a topical skin lesion treatment.
BFRA is also working to expand the range of indications for Ameluz.
I’ll provide a final opinion when we learn more details about the IPO.
The firm is a biopharmaceutical company which develops, sells, and distributes dermatological drugs and medical cosmetics. Biofrontera AG’s main focus is the treatment of actinic keratoses, skin lesions that can lead to skin cancer.
BFRA is both commercializing its lead candidate and developing additional indication applications.
When we learn more details about the IPO, I’ll provide a final opinion on my Seeking Alpha Marketplace research service, IPO Edge.
Leverkusen, Germany-based Biofrontera AG was founded in 1997 to develop and commercialize products for the treatment of dermatological conditions and diseases caused by sun damage to the skin. The company operates in the actinic keratoses market.
Management is headed by CEO and Managing Director Hermann Lubbert, who has been with the firm since inception. Prior to serving at Biofrontera, Lubbert was involved in global research management at Sandoz and Novartis Pharma AG for ten years.
The company’s products focus on the U.S. and Europe for treatment of actinic keratoses and also basal cell carcinoma in the EU. Biofrontera’s main product is Ameluz, a prescription drug approved to be used in combination with the company’s medical device BF-RhodoLED for the photodynamic therapy (PDT) treatment of superficial skin cancer and its precursors.